about
Risk Factors for Death of Patients with Cystic Fibrosis Awaiting Lung TransplantationCo-registration of acquired MR ventilation and perfusion images--validation in a porcine model.Perfusion scintigraphy and patient selection for lung volume reduction surgeryAlternatives to lung transplantation: lung volume reduction surgery and continuous intravenous prostacyclin.Bronchoscopy for atelectasis in the ICU: a case report and review of the literature.Redefining treatment in COPD: new directions in bronchodilator therapy.Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient.Measurements of regional alveolar oxygen pressure using hyperpolarized 3He MRI.A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation.FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease.A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome.A small animal model of regional alveolar ventilation using HP 3He MRI1.A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome.Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial.The adenosine 2A receptor agonist GW328267C improves lung function after acute lung injury in rats.Determination of regional VA/Q by hyperpolarized 3He MRI.Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.Effects of umeclidinium/vilanterol on exercise endurance in COPD: a randomised study.Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1.A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol.Giant gastric ulcers and risk factors for gastroduodenal mucosal disease in orthotopic lung transplant patients.Pulmonary ventilation and perfusion scanning using hyperpolarized helium-3 MRI and arterial spin tagging in healthy normal subjects and in pulmonary embolism and orthotopic lung transplant patientsApical Perfusion Fraction as a Predictor of Short-term Functional Outcome Following Bilateral Lung Volume Reduction SurgeryDynamic observation of pulmonary perfusion using continuous arterial spin-labeling in a pig modelPost-mortem stability of thyrotropin-releasing hormone and muscarinic cholinergic receptors in rat forebrainTension pneumoperitoneum associated with a pleural-peritoneal shuntConversion to tacrolimus (FK506) from cyclosporine after orthotopic lung transplantationDetection of simulated pulmonary embolism in a porcine model using hyperpolarized 3He MRITiotropium bromideDirect visualisation of collateral ventilation in COPD with hyperpolarised gas MRI(3)He pO2 mapping is limited by delayed-ventilation and diffusion in chronic obstructive pulmonary diseaseReply: "FULFIL an Unmet Need in Chronic Obstructive Pulmonary Disease" and "Triple Therapy in Chronic Obstructive Pulmonary Disease"Efficacy of Umeclidinium/Vilanterol in Elderly Patients with COPD: A Pooled Analysis of Randomized Controlled TrialsThe IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese PopulationThe Effect of Exacerbation History on Outcomes in the IMPACT TrialPopulation Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary DiseaseMisinterpretation of time-to-first event curves can lead to inappropriate treatmentEfficacy and Safety of Once-Daily Inhaled Umeclidinium in Asian Patients with COPD: Results from a Randomized, Placebo-Controlled Study
P50
Q22306317-4266C072-E130-4C22-B8E0-D10009FE4452Q31123563-56D13033-CE93-4498-9018-54680DFBA9F2Q34269056-6AB7D6E6-CA5F-4A05-9FB4-00E16D42428CQ34693428-97116261-B537-4BE6-8F88-B8D73640E448Q35174660-5FD28226-ACAB-4743-8DF2-B6E01DB62070Q35795125-808390A7-A712-4E20-A9E5-18671CF8B88AQ36176663-DB6466C3-6E98-4DBF-9909-61A2C9BD8742Q36299100-F25A7CA2-CF89-40E3-9561-89615716E381Q37119845-09FD4EE9-13E4-4787-A68D-6BDE22B53BDBQ38856068-C5801600-3FFD-48DE-8EBF-25B8932CDDCDQ38992629-BBEB92F0-CC94-44DB-9AFD-F8A6F1248081Q40469979-864D3F61-BC1A-484D-9C7E-A36EED2C2426Q41592036-B62B71A5-3ECE-4739-89E3-0FCF23BFAB78Q41844550-C65B3E77-00FB-4F65-A7ED-33C8E83751C4Q44183959-143570D7-B1BE-4240-93BD-56B1C5B7BEE6Q44965422-CF64AFC2-68CE-41CA-83E2-F211CD40D97FQ47122143-2D8066D2-9B58-4B5C-BE45-1DD20CFA7B9AQ47192702-C3BE413C-B5BF-450A-9D2A-3CF9680B9169Q47647326-ADED88F9-8D2B-472C-8681-323639CC10DDQ47660372-097C0A05-52CB-4AEB-8AF1-CB8DC1E2AB05Q50853563-50FD368A-988D-4F0F-AABD-5230C57CC9F4Q51490048-28AC86CC-E824-4900-981F-2C73F8B21FD0Q54545068-543DCC23-9C80-4250-AA71-AEEDBB5192F7Q60153718-2B6A3DE0-EAD9-4C5F-B932-FCE1ADCD4180Q60153719-5B35020D-4D38-4380-93B1-22D9AFA1BEDAQ60153720-53368B39-01DE-4654-B437-62C44D1FDD78Q69361838-E87E2E6C-35A2-462D-B4D5-A9E5E1AB2DA8Q73007333-9F18E623-7D83-4450-8200-51C7CC2289B6Q74686194-868F3525-D985-4547-95A0-39E00A0DC5B9Q75383791-6B79BBCC-EDE6-465D-A2FD-7CC9A2DA69DEQ80115301-CD294370-34CF-46F9-AE7C-58DCA0F123AFQ83352648-1D07C7B9-A1FE-424F-A2C3-8595F9EE7AA0Q86757214-527FFA61-EF08-4F06-BAEA-84CFB9FF9A91Q88128539-DAC56044-D2B9-4B66-A89B-55AB6906D167Q89303141-7D45EE96-119D-447B-803C-530E959AB542Q91992488-8CC58030-5658-4AFD-9847-9BBB8976BA35Q91997438-FB18A767-8CA0-4EC8-BCB2-1B1BC79BB92BQ92011261-379D2630-34CD-44E9-A05E-7436217ED8B9Q93132017-51DFA215-3BC0-4EEE-B6F5-D19239FB9EEDQ94525576-3860D10A-48FF-41E7-B43F-0984866454F5
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
David A. Lipson
@ast
David A. Lipson
@en
David A. Lipson
@es
David A. Lipson
@nl
David A. Lipson
@sl
type
label
David A. Lipson
@ast
David A. Lipson
@en
David A. Lipson
@es
David A. Lipson
@nl
David A. Lipson
@sl
prefLabel
David A. Lipson
@ast
David A. Lipson
@en
David A. Lipson
@es
David A. Lipson
@nl
David A. Lipson
@sl
P106
P1153
7006039053
P21
P31
P496
0000-0001-6732-4593